DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Should l Buy DRIO?
Source: PRnewswire
Study Findings: A peer-reviewed study by Sanofi and Symphony Health revealed that Dario's digital diabetes intervention platform resulted in 23% lower hospitalization rates and 26% lower healthcare charges compared to usual care for type 2 diabetes patients.
Engagement Impact: Increased engagement with the Dario platform was associated with fewer inpatient and emergency room events, highlighting the effectiveness of continuous digital health support.
Economic Validation: The study provided strong evidence that digital health interventions can significantly reduce healthcare costs and utilization, addressing key concerns of payers and employers regarding the financial impact of such solutions.
DarioHealth Overview: DarioHealth is a digital health company focused on chronic condition management, offering personalized interventions through a user-centric platform that aims to improve health outcomes and reduce costs for users and healthcare systems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRIO
Wall Street analysts forecast DRIO stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 8.125
Low
11.00
Averages
13.50
High
16.00
Current: 8.125
Low
11.00
Averages
13.50
High
16.00
About DRIO
DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DarioHealth to Release Q1 Financial Results on May 13
- Earnings Release Schedule: DarioHealth will host a conference call on May 13, 2026, at 8:30 a.m. Eastern Time to discuss its Q1 financial results for the period ending March 31, 2026, which is expected to provide investors with critical financial data and future outlook.
- Executive Participation: CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda will co-host the call, ensuring that investors receive insights and analyses directly from the company's leadership team.
- Participation Details: Investors can join the call by dialing 1-800-717-1738 for domestic or 1-646-307-1865 for international access, or use the provided “Call me™” link for instant access, enhancing participation convenience.
- Replay Information: A replay of the call will be available approximately three hours after the conclusion of the conference, allowing investors who could not attend live to access important information by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international) with replay passcode 1111468.
See More
DarioHealth to Release Q1 Financial Results on May 13
- Earnings Release Schedule: DarioHealth will host a conference call on May 13, 2026, at 8:30 a.m. Eastern Time to discuss its Q1 financial results for the period ending March 31, 2026, providing investors with insights into the company's financial health and future outlook.
- Executive Participation: The call will feature CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda, ensuring that investors receive direct insights and analyses from the company's leadership team.
- Participation Details: Investors can join the call by dialing 1-800-717-1738 for domestic or 1-646-307-1865 for international access, or use the provided
See More
DarioHealth's New Study Enhances Workplace Performance
- Workplace Function Improvement: DarioHealth's new study reveals that 1,254 users of its digital behavioral health program showed significant improvements in focus within six weeks, indicating the program's substantial economic value in enhancing employee daily performance.
- Reduction in Procrastination and Errors: Among 1,004 users reporting procrastination, the study found a notable decrease in workplace mistakes after using Dario's solutions, underscoring the strong link between behavioral health and workplace efficiency.
- Significant Economic Impact: U.S. employers face an estimated $575 billion annual loss due to illness-related absenteeism and presenteeism, and Dario's solutions help mitigate these costs by improving employees' health management capabilities, thereby boosting overall productivity.
- Importance of Continuous Support: The research emphasizes the critical role of ongoing behavioral support in enhancing employees' daily functioning, further validating Dario's effective approach of integrating behavioral science with data-driven insights to foster sustainable health habits.
See More
DarioHealth (DRIO) Q4 2025 Earnings Transcript
See More
DarioHealth Reports Q4: Net Loss Up 32% Amid Revenue Shift
- Financial Performance Decline: DarioHealth's Q4 non-GAAP net loss increased by 32% to $6.5 million, reflecting the financial pressures faced during the company's transition.
- Significant Revenue Drop: The company reported revenue of $5.2 million, a 31.6% year-over-year decline, although it beat expectations by $0.15 million, primarily due to the shift from one-time revenues to annual recurring revenues (ARR).
- Client Relationship Changes: A significant scope change with a large national health plan client resulted in revenue decline, as this client was not renewed at the beginning of 2025, highlighting challenges in client retention for DarioHealth.
- Strategic Transition Impact: DarioHealth is focusing on its core B2B2C business, and while facing revenue fluctuations in the short term, the long-term strategic intent is to enhance sustainable revenue sources.
See More
DarioHealth Reports 2023 Earnings Decline
- Revenue Decline: DarioHealth's revenue for 2023 was $22.35 million, down 17.3% from $27.04 million last year, indicating pressure in market competition that could affect future investor confidence.
- Earnings Per Share Shift: The company's EPS stood at $10.12, a decrease from $12.27 last year, reflecting weakened profitability that may raise shareholder concerns about the company's earnings outlook.
- Overall Profitability: DarioHealth reported a full-year profit of $61.73 million, which, while an absolute increase, did not offset the revenue decline compared to last year's $40.98 million, highlighting challenges faced by the company.
- Market Reaction Outlook: Given the dual decline in revenue and EPS, the market is expected to adopt a cautious stance towards DarioHealth's future performance, potentially impacting its stock price trajectory and investor confidence.
See More
DarioHealth to Release Q1 Financial Results on May 13
- Earnings Release Schedule: DarioHealth will host a conference call on May 13, 2026, at 8:30 a.m. Eastern Time to discuss its Q1 financial results for the period ending March 31, 2026, which is expected to provide investors with critical financial data and future outlook.
- Executive Participation: CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda will co-host the call, ensuring that investors receive insights and analyses directly from the company's leadership team.
- Participation Details: Investors can join the call by dialing 1-800-717-1738 for domestic or 1-646-307-1865 for international access, or use the provided “Call me™” link for instant access, enhancing participation convenience.
- Replay Information: A replay of the call will be available approximately three hours after the conclusion of the conference, allowing investors who could not attend live to access important information by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international) with replay passcode 1111468.
See More
DarioHealth to Release Q1 Financial Results on May 13
- Earnings Release Schedule: DarioHealth will host a conference call on May 13, 2026, at 8:30 a.m. Eastern Time to discuss its Q1 financial results for the period ending March 31, 2026, providing investors with insights into the company's financial health and future outlook.
- Executive Participation: The call will feature CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda, ensuring that investors receive direct insights and analyses from the company's leadership team.
- Participation Details: Investors can join the call by dialing 1-800-717-1738 for domestic or 1-646-307-1865 for international access, or use the provided
See More
DarioHealth's New Study Enhances Workplace Performance
- Workplace Function Improvement: DarioHealth's new study reveals that 1,254 users of its digital behavioral health program showed significant improvements in focus within six weeks, indicating the program's substantial economic value in enhancing employee daily performance.
- Reduction in Procrastination and Errors: Among 1,004 users reporting procrastination, the study found a notable decrease in workplace mistakes after using Dario's solutions, underscoring the strong link between behavioral health and workplace efficiency.
- Significant Economic Impact: U.S. employers face an estimated $575 billion annual loss due to illness-related absenteeism and presenteeism, and Dario's solutions help mitigate these costs by improving employees' health management capabilities, thereby boosting overall productivity.
- Importance of Continuous Support: The research emphasizes the critical role of ongoing behavioral support in enhancing employees' daily functioning, further validating Dario's effective approach of integrating behavioral science with data-driven insights to foster sustainable health habits.
See More
DarioHealth (DRIO) Q4 2025 Earnings Transcript
See More
DarioHealth Reports Q4: Net Loss Up 32% Amid Revenue Shift
- Financial Performance Decline: DarioHealth's Q4 non-GAAP net loss increased by 32% to $6.5 million, reflecting the financial pressures faced during the company's transition.
- Significant Revenue Drop: The company reported revenue of $5.2 million, a 31.6% year-over-year decline, although it beat expectations by $0.15 million, primarily due to the shift from one-time revenues to annual recurring revenues (ARR).
- Client Relationship Changes: A significant scope change with a large national health plan client resulted in revenue decline, as this client was not renewed at the beginning of 2025, highlighting challenges in client retention for DarioHealth.
- Strategic Transition Impact: DarioHealth is focusing on its core B2B2C business, and while facing revenue fluctuations in the short term, the long-term strategic intent is to enhance sustainable revenue sources.
See More
DarioHealth Reports 2023 Earnings Decline
- Revenue Decline: DarioHealth's revenue for 2023 was $22.35 million, down 17.3% from $27.04 million last year, indicating pressure in market competition that could affect future investor confidence.
- Earnings Per Share Shift: The company's EPS stood at $10.12, a decrease from $12.27 last year, reflecting weakened profitability that may raise shareholder concerns about the company's earnings outlook.
- Overall Profitability: DarioHealth reported a full-year profit of $61.73 million, which, while an absolute increase, did not offset the revenue decline compared to last year's $40.98 million, highlighting challenges faced by the company.
- Market Reaction Outlook: Given the dual decline in revenue and EPS, the market is expected to adopt a cautious stance towards DarioHealth's future performance, potentially impacting its stock price trajectory and investor confidence.
See More
